Long term improvement in dyslipidaemia in Type 2 diabetes with bezafibrate is not related to changes in insulin resistance.
Elkeles
R S
RS
Diamond
J R
JR
Anyaoku
V
V
Hughes
C
C
Richmond
W
W
D001629:Bezafibrate / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000503:physiopathology*; D005500:Follow-Up Studies; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D008075:Lipoproteins, HDL / Q000187:drug effects; D008077:Lipoproteins, LDL / Q000187:drug effects; D012016:Reference Values; D016896:Treatment Outcome
D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D001629:Bezafibrate